FGF23: Fibroblast growth factor 23
Regulator of phosphate homeostasis.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on FGF23, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Burosumab | Approved | Kyowa Kirin | Antibody | InhibitorFibroblast growth factor 23 inhibitor | 6 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 6 in all, from ClinicalTrials.gov.| Effective Dosing of Burosumab in XLH | Burosumab | — | Recruiting | University of Nottingham | Sep 19, 2025 |
| Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients | Burosumab | — | Recruiting | Kyowa Kirin Korea Co., Ltd. | Jan 11, 2024 |
| Tumor-induced Osteomalacia Disease Monitoring Program | Burosumab | — | Active, not recruiting | Ultragenyx Pharmaceutical Inc | Mar 5, 2021 |
| Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts | Burosumab | — | Recruiting | Hospices Civils de Lyon | Nov 12, 2019 |
| X-linked Hypophosphatemia Disease Monitoring Program | Burosumab | — | Active, not recruiting | Ultragenyx Pharmaceutical Inc | Aug 29, 2018 |
| Registry for Patients With X-Linked Hypophosphatemia | Burosumab | — | Recruiting | Kyowa Kirin Pharmaceutical Development Ltd | Jun 20, 2017 |
Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Autosomal dominant hypophosphatemic rickets
- 0.76
- Tumoral calcinosis, hyperphosphatemic, familial, 2
- 0.73
- Familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome
- 0.62
- Cancer
- 0.61
- Bone development disease
- 0.60
- X-linked dominant hypophosphatemic rickets
- 0.58
- Osteomalacia
- 0.55
- Hypophosphatemic rickets
- 0.53
- Hypophosphatemia
- 0.52
- Familial tumoral calcinosis
- 0.39
- Ovarian carcinoma
- 0.38
- Bone disorder
- 0.38
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3713913, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q9GZV9, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets